Pediatric Hematology/Oncology and ImmunopathologyPediatric Hematology/Oncology and ImmunopathologyВопросы гематологии/онкологии и иммунопатологии в педиатрии1726-17082414-9314Fund Doctors, Innovations, Science for Children18410.24287/1726-1708-2018-17-2-121-135LITERATURE REVIEWОБЗОР ЛИТЕРАТУРЫNew advances in pathogenesis, diagnostic and treatment of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantationНовое в патогенезе, диагностике и лечении хронической реакции «трансплантат против хозяина» после аллогенной ТГСКhttps://orcid.org/0000-0002-0566-053XSkvortsovaY. V.СкворцоваЮ.В.
Russian Federation

MD, hematologist of HSCT Department #2

Russia 117997, Moscow, Samory Mashela st., 1

yuscvo@mail.ruhttps://orcid.org/0000-0002-2322-5734NovichkovaG. A.НовичковаГ.А.
Russian Federation
https://orcid.org/0000-0002-0016-6698MaschanA. A.МасчанА.А.
Russian Federation
Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, ImmunologyФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России2009201817212113520092018Copyright ©; 1970, «D. Rogachev NMRCPHOI»Copyright ©; 1970, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России1970«D. Rogachev NMRCPHOI»ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава Россииhttps://creativecommons.org/licenses/by/4.0https://hemoncim.com/jour/article/view/184

Chronic GVHD remains a serious complication of allogeneic HSCT, leading to impairment of numerous organs and systems. It is characterised by the combination of auto- and alloimmune dysregulation, immunodeficiency and low quality of life. The incidence of chronic GVHD in allogeneic HSCT setting is 30–70% in adults and 15–40% in children. The problems of diagnostic and treatment of chronic GVHD are associated with poor measuring and scoring validation system. This literature review describes modern insights in chronic GVHD pathophysiology, international diagnosing criteria and new treatment approaches.

Хроническая реакция «трансплантат против хозяина» (РТПХ) остается ведущим осложнением аллогенной трансплантации гемопоэтических стволовых клеток (ТГСК), определяющим поражение множества органов и систем, и характеризуется комбинацией ауто- и аллоиммунной дисрегуляции, формированием иммунного дефицита и нарушением качества жизни. Частота возникновения хронической РТПХ при аллогенных ТГСК составляет 30-70% у взрослых и 15-40% у детей. Сложности в диагностике и лечении хронической РТПХ связаны с проблемами унификации оценки поражения и степени ее тяжести. В данном обзоре описаны современные воззрения на патогенез, международные критерии диагностики, представлены новые подходы к терапии данного осложнения.

chronic graft-versus host diseaseallogeneic HSCTхроническая реакция «трансплантат против хозяина»аллогенная трансплантация гемопоэтических стволовых клетокBarnes D.W., Loutit J.F. The radiation recovery factor: preservation by the Polge-Smith-Parkes technique. J Natl Cancer Inst 1955; 15 (4): 901-5.Billingham R.E. The biology of graft-versus-host reactions. Harvey Lect 1966-1967; 62: 21-78.Jagasia M.H., Greinix H.T., Arora M., Williams K.M., Wolff D., Cowen E.W., et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2015; 21 (3): 389-401.Pidala J., Vogelsang G., Martin P., Chai X., Storer B., Pavletic S., et al. Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study. Haematologica 2012; 97 (3): 451-8.Lee S.J. Flowers M.E. Recognizing and managing chronic graft-versus-host disease. Hematology Am Soc Hematol Educ Program 2008: 134-41.Rocha V., Wagner J.E.Jr, Sobocinski K.A., Klein J.P., Zhang M.J., Horowitz M.M., Gluckman E. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med 2000; 342 (25): 1846-54.Eapen M., Rubinstein P., Zhang M.J., Stevens C., Kurtzberg J., Scaradavou A., et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet 2007; 369 (9577): 1947-54.Bunin N.J., Davies S.M., Aplenc R., Camitta B.M., DeSantes K.B., Goyal R.K., et al. Unrelated donor bone marrow transplantation for children with acute myeloid leukemia beyond first remission or refractory to chemotherapy. J Clin Oncol 2008; 26 (26): 4326-32.Arora M., Klein J.P., Weisdorf D.J., Hassebroek A., Flowers M.E., Cutler C.S., et al. Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood 2011;117 (24): 6714-20.Flowers M.E., Martin P.J. How we treat chronic graft-versus-host disease. Blood 2015; 125 (4): 606-15.Martin P.J., Counts G.W.Jr., Appelbaum F.R., Lee S.J., Sanders J.E., Deeg H.J., et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol 2010; 28 (6): 1011-6.Wingard J.R., Majhail N.S., Brazauskas R., Wang Z., Sobocinski K.A., Jacobsohn D., et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol 2011; 29 (16): 2230-9.Arai S., Jagasia M., Storer B., Chai X., Pidala J., Cutler C, et al. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood 2011; 118 (15): 4242-9.Jacobsohn D.A., Kurland B.F., Pidala J., Inamoto Y., Chai X., Palmer J.M., et al. Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. Blood 2012; 120 (13): 2545-52.Shulman H.M., Cardona D.M., Greenson J.K., Hingorani S., Horn T., Huber E., et al. NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease:II. The 2014 Pathology Working Group Report. Biol Blood Marrow Transplant 2015; 21 (4): 589-603.Martin P.J., Lee S.J., Przepiorka D., Horowitz M.M., Koreth J., Vogelsang G.B., et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report. Biol Blood Marrow Transplant 2015; 21 (8): 1343-59.Blazar B.R., Murphy W.J., Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol 2012; 12 (6): 443-58.Chu Y.W., Gress R.E. Murine models of chronic graft-versus-host disease: insights and unresolved issues. Biol Blood Marrow Transplant 2008; 14 (4): 365-78.Schroeder M.A., DiPersio J.F. Mouse models of graft-versus-host disease: advances and limitations. Dis Model Mech 2011; 4 (3): 318-33.Shlomchik W.D., Lee S.J., Couriel D., Pavletic S.Z. Transplantation's greatest challenges: advances in chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007; 13 (1 Suppl 1): 2-10.Socié G., Ritz J. Current issues in chronic graft-versus-host disease. Blood 2014; 124 (3): 374-84.Flowers M.E., Inamoto Y., Carpenter P.A., Lee S.J., Kiem H.P., Petersdorf E.W., et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 2011; 117 (11): 3214-9.Filipovich A.H., Weisdorf D., Pavletic S., Socie G., Wingard J.R., Lee S.J., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11 (12): 945-56.Lee S.J., Klein J.P., Barrett A.J., Ringden O., Antin J.H., Cahn J.Y., et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002 Jul 15; 100 (2): 406-14.Arora M., Nagaraj S., Witte J., DeFor T.E., MacMillan M., Burns L.J., Weisdorf D.J. New classification of chronic GVHD: added clarity from the consensus diagnoses. Bone Marrow Transplant 2009; 43 (2): 149-53.Moon J.H., Sohn S.K., Lambie A., Ellis L., Hamad N., Uhm J., et al. Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival. Biol Blood Marrow Transplant 2014; 20 (4): 556-63.Jacobsohn D.A., Schechter T., Seshadri R., Thormann K., Duerst R., Kletzel M. Eosinophilia correlates with the presence or development of chronic graft-versus-host disease in children. Transplantation 2004; 77 (7): 1096-100.Shultz K. Pathophysiology of chronic graft versus host disease. In: Vogelsang B, Pavlitic S, eds. Chronic Graft-Versus-Host Disease: Interdisciplinary Management. Vol. 1 New York, NY: Cambridge University Press; 2009: 17-30.Fujii H., Cuvelier G., She K., Aslanian S., Shimizu H., Kariminia A., et al. Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group. Blood 2008; 111 (6): 3276-85.Nakasone H., Binh P.N., Yamazaki R., Tanaka Y., Sakamoto K., Ashizawa M., et al. Association between serum high-molecular-weight adiponectin level and the severity of chronic graft-versus-host disease in allogeneic stem cell transplantation recipients. Blood 2011; 117 (12): 3469-72.Kitko C.L., Levine J.E., Storer B.E., Chai X., Fox D.A., Braun T.M., et al. Plasma CXCL9 elevations correlate with chronic GVHD diagnosis. Blood 2014; 123 (5): 786-93.Palmer J.M., Lee S.J., Chai X., Storer B.E., Flowers M.E., Schultz K.R., et al. Poor agreement between clinician response ratings and calculated response measures in patients with chronic graft-versus-host disease. Biol Blood Marrow Transplant 2012; 18 (11): 1649-55.MacDonald K.P., Hill G.R., Blazar B.R. Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. Blood 2017; 129 (1): 13-21.Yi T., Chen Y., Wang L., Du G., Huang D., Zhao D., et al. Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood 2009; 114 (14): 3101-12.Carlson M.J., West M.L., Coghill J.M., Panoskaltsis-Mortari A., Blazar B.R., Serody J.S. In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood 2009; 113 (6): 1365-74.Serody J.S., Hill G.R. The IL-17 differentiation pathway and its role in transplant outcome. Biol Blood Marrow Transplant 2012; 18 (1 Suppl): S56-61.Jin H., Ni X., Deng R., Song Q., Young J., Cassady K., et al. Antibodies from donor B cells perpetuate cutaneous chronic graft-versus-host disease in mice. Blood 2016; 127 (18): 2249-60.Miklos D.B., Kim H.T., Miller K.H., Guo L., Zorn E, Lee S.J, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005; 105 (7): 2973-8.Alexander K.A., Flynn R., Lineburg K.E., Kuns R.D., Teal B.E., Olver S.D., et al. CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease. J Clin Invest 2014; 124 (10): 4266-80.Svegliati S., Olivieri A., Campelli N., Luchetti M., Poloni A., Trappolini S., et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 2007; 110 (1): 237-41.Erbel C., Akhavanpoor M., Okuyucu D., Wangler S., Dietz A., Zhao L., et al. IL-17A influences essential functions of the monocyte/macrophage lineage and is involved in advanced murine and human atherosclerosis. J Immunol 2014; 193 (9): 4344-55.Sage P.T., Sharpe A.H. T follicular regulatory cells. Immunol Rev 2016; 271 (1): 246-59.Zorn E., Kim H.T., Lee S.J., Floyd B.H., Litsa D., Arumugarajah S., et al. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood 2005; 106 (8): 2903-11.Matsuoka K., Kim H.T., McDonough S., Bascug G., Warshauer B., Koreth J., et al. Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J Clin Invest 2010; 120 (5): 1479-93.Leveque-El Mouttie L., Koyama M., Le Texier L., Markey K.A., Cheong M., et al. Corruption of dendritic cell antigen presentation during acute GVHD leads to regulatory T-cell failure and chronic GVHD. Blood 2016; 128 (6): 794-804.de Masson A., Bouaziz J.D., Le Buanec H., Robin M., O'Meara A., Parquet N., et al. CD24(hi)CD27⁺ and plasmablast-like regulatory B cells in human chronic graft-versus-host disease. Blood 2015; 125 (11): 1830-9.Lee S.J., Vogelsang G., Flowers M.E. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003; 9 (4): 215-33.Inamoto Y., Martin P.J., Chai X., Jagasia M., Palmer J., Pidala J., et al. Chronic GVHD Consortium. Clinical benefit of response in chronic graft-versus-host disease. Biol Blood Marrow Transplant 2012; 18 (10): 1517-24.Martin P.J., Storer B.E., Carpenter P.A., Couriel D.R., Flowers M.E., Gupta V., et al. Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2011; 17 (1): 124-32.Socié G., Schmoor C., Bethge W.A., Ottinger H.D., Stelljes M., Zander A.R., et al.; ATG-Fresenius Trial Group. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood 2011; 117 (23): 6375-82.Finke J., Bethge W.A., Schmoor C., Ottinger H.D., Stelljes M., Zander A.R., et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. ATG-Fresenius Trial Group. Lancet Oncol 2009; 10 (9): 855-64.Bacigalupo A., Lamparelli T., Barisione G., Bruzzi P., Guidi S., Alessandrino P.E., et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006; 12 (5): 560-5.Cutler C., Kim H.T., Bindra B., Sarantopoulos S., Ho V.T., Chen Y.B., et al. Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. Blood 2013; 122 (8): 1510-7.Arai S., Sahaf B., Narasimhan B., Chen G.L., Jones C.D., Lowsky R., et al. Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood 2012; 119 (25): 6145-54.Soiffer R.J., Lerademacher J., Ho V., Kan F., Artz A., Champlin R.E., et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 2011; 117 (25): 6963-70.Devine S.M., Carter S., Soiffer R.J., Pasquini M.C., Hari P.N., Stein A., et al. Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303. Biol Blood Marrow Transplant 2011; 17 (9): 1343-51.Luznik L., Bolaños-Meade J., Zahurak M., Chen A.R., Smith B.D., Brodsky R., et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 2010; 115 (16): 3224-30.Raj K., Pagliuca A., Bradstock K., Noriega V., Potter V., Streetly M., et al. Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning. Biol Blood Marrow Transplant 2014; 20 (6): 890-5.Wolff D., Schleuning M., von Harsdorf S., Bacher U., Gerbitz A., Stadler M., et al. Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 2011; 17 (1): 1-17.Inamoto Y., Flowers M.E. Treatment of chronic graft-versus-host disease in 2011. Curr Opin Hematol 2011; 18 (6): 414-20.Koc S., Leisenring W., Flowers M.E., Anasetti C., Deeg H.J., Nash R.A., et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood 2002; 100 (1): 48-51.Koc S., Leisenring W., Flowers M.E., Anasetti C., Deeg H.J., Nash R.A., et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood 2002; 100 (1): 48-51.Martin P.J., Inamoto Y., Carpenter P.A., Lee S.J., Flowers M.E. Treatment of chronic graft-versus-host disease: Past, present and future. Korean J Hematol 2011; 46 (3): 153-63.Martin P.J., Storer B.E., Rowley S.D., Flowers M.E., Lee S.J., Carpenter P.A., et al. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood 2009; 113 (21): 5074-82.Flowers M.E., Storer B., Carpenter P., Rezvani A.R., Vigorito A.C., Campregher P.V., et al. Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease. Biol Blood Marrow Transplant 2008; 14 (12): 1380-4.Inamoto Y., Flowers M.E., Sandmaier B.M., Aki S.Z., Carpenter P.A., Lee S.J., et al. Failure-free survival after initial systemic treatment of chronic graft-versus-host disease. Blood 2014; 124 (8): 1363-71.Greinix H.T., Worel N., Just U., Knobler R. Extracorporeal photopheresis in acute and chronic graft-versus-host disease. Transfus Apher Sci 2014; 50(3): 349-57.Flowers M.E., Apperley J.F., van Besien K., Elmaagacli A., Grigg A., Reddy V., et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood 2008; 112 (7): 2667-74.Olivieri A., Cimminiello M., Corradini P., Mordini N., Fedele R., Selleri C., et al. Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD. Blood 2013; 122 (25): 4111-8.de Masson A., Bouaziz J.D., Peffault de Latour R., Wittnebel S., Ribaud P., Rubio M.T., et al. Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD. Blood 2012; 120 (25): 5089-90.Salvaneschi L., Perotti C., Zecca M., Bernuzzi S., Viarengo G., Giorgiani G., et al. Extracorporeal photochemotherapy for treatment of acute and chronic GVHD in childhood. Transfusion 2001; 41 (10): 1299-305.Sniecinski I., Seghatchian J. Factual reflections and recommendations on extracorporeal photopheresis in pediatrics. Transfus Apher Sci 2017; 56 (2): 118-122.Mohammadi S., Malek Mohammadi A., Norooznezhad A.H., Heshmati F., Alimoghaddam K., Ghavamzadeh A. Extra corporeal photochemotherapy in steroid refractory graft versus host disease: A review of guidelines and recommendations. Transfus Apher Sci 2017; 56 (3): 376-384.Koreth J., Matsuoka K., Kim H.T., McDonough S.M., Bindra B., Alyea E.P. 3rd, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011; 365 (22): 2055-66.Koreth J., Matsuoka K., Kim H.T., McDonough S.M., Bindra B., Alyea E.P. 3rd, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011; 365 (22): 2055-66.Matsuoka K., Koreth J., Kim H.T., Bascug G., McDonough S., Kawano Y., et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med 2013; 5 (179): 179ra43.Apperly J., Masszi T. Graft-versus-host disease. In: The 2012 revised edition of the EBMT-ESH Handbook on Haematopoietic Stem Cell Transplantation. Editors: J. Apperley, E. Carreras, E. Gluckman, T. Masszi. 6th Edition. Chapter 13; 217-33.Martelli M.F., Di Ianni M., Ruggeri L., Falzetti F., Carotti A., Terenzi A., et al. HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. Blood 2014; 124 (4): 638-44.Reisner Y., Aversa F., Martelli M.F. Haploidentical hematopoietic stem cell transplantation: state of art. Bone Marrow Transplant 2015; 50 Suppl 2: S1-5.Robinson T.M., O'Donnell P.V., Fuchs E.J., Luznik L. Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide. Semin Hematol 2016; 53 (2): 90-7.Yu Y., Wang D., Liu C., Kaosaard K., Semple K., Anasetti C., Yu X.Z. Prevention of GVHD while sparing GVL effect by targeting Th1 and Th17 transcription factor T-bet and RORγt in mice. Blood 2011; 118 (18): 5011-20.Cohen J.L., Trenado A., Vasey D., Klatzmann D., Salomon B.L. CD4(+)CD25(+) immunoregulatory T Cells: new therapeutics for graft-versus-host disease. J Exp Med 2002; 196 (3): 401-6.Di Ianni M., Falzetti F., Carotti A., Terenzi A., Castellino F., Bonifacio E., et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011; 117 (14): 3921-8.Brunstein C.G., Miller J.S., McKenna D.H., Hippen K.L., DeFor T.E., Sumstad D., et al. Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. Blood 2016; 127 (8): 1044-51.Koreth J., Kim H.T., Jones K.T., Lange P.B., Reynolds C.G., Chammas M.J., et al. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. Blood 2016; 128 (1): 130-7.Arai S., Pidala J., Pusic I., Chai X., Jaglowski S., Khera N., et al. A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation. Clin Cancer Res 2016; 22 (2): 319-27.Flynn R., Allen J.L., Luznik L., MacDonald K.P., Paz K., Alexander K.A., et аl. Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. Blood 2015; 125 (26): 4085-94.Dubovsky J.A., Flynn R., Du J., Harrington B.K., Zhong Y., Kaffenberger B., et al. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest 2014; 124 (11): 4867-76.Flynn R., Paz K., Du J., Reichenbach D.K., Taylor P.A., Panoskaltsis-Mortari A., et al. Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood 2016; 127 (17): 2144-54.Spoerl S., Mathew N.R., Bscheider M., Schmitt-Graeff A., Chen S., Mueller T., et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood 2014; 123 (24): 3832-42.Zeiser R., Burchert A., Lengerke C., Verbeek M., Maas-Bauer K., Metzelder S.K., et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia 2015; 29 (10): 2062-8.Pai C.C., Chen M., Mirsoian A., Grossenbacher S.K., Tellez J. Ames E., et al. Treatment of chronic graft-versus-host disease with bortezomib. Blood 2014; 124(10): 1677-88.Banovic T., MacDonald K.P., Morris E.S., Rowe V., Kuns R., Don A., et al. TGF-beta in allogeneic stem cell transplantation: friend or foe? Blood 2005; 106(6): 2206-14.Im A., Hakim F.T., Pavletic S.Z. Novel targets in the treatment of chronic graft-versus-host disease. Leukemia 2017; 31(3): 543-54.Carpenter P.A., Kitko C.L., Elad S., Flowers M.E., Gea-Banacloche J.C., Halter J.P., et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 2015; 21 (7): 1167-87.Couriel D., Carpenter P.A., Cutler C., Bolaños-Meade J., Treister N.S., Gea-Banacloche J., et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 2006; 12(4): 375-96.Vigorito A.C., Campregher P.V., Storer B.E., Carpenter P.A., Moravec C.K., Kiem H.P., et al. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood 2009; 114(3): 702-8.Inamoto Y., Storer B.E., Petersdorf E.W., Nelson J.L., Lee S.J., Carpenter P.A., et al. Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease. Blood 2013; 121 (25): 5098-103.Akpek G., Lee S.J., Flowers M.E., Pavletic S.Z., Arora M., Lee S., et al. Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study. Blood 2003; 102 (3): 802-9.